The Phase 2 proof-of-concept clinical trial of SGX942 for the treatment of oral mucositis
in head and neck cancer patients remains consistent with prior guidance.
However, while in vivo animal models of chemotherapy and radiotherapy-induced oral mucositis
have been successfully established, alternative methods such as in vitro tools for mucositis
are still missing.
is a common side effect of cancer treatments with approximately 1.
An evidence-based protocol for dental care with specific treatment modalities, including the prevention and treatment of oral mucositis
(OM), is included.
Lactobacillus brevis CD2 lozenges reduce radiation-and chemotherapy-induced mucositis
in patients with head and neck cancer: A randomized double-blind placebo-controlled study.
The most important side effects of oncologic therapy are ulcerations, alopecia, thrombocytopenia, neutropenia and oropharyngeal mucositis
(OM) is a common side effect of chemotherapy and radiation therapy.
Susan Sencer, MD, medical director, Hematology/Oncology, presented findings on the use of the homeopathic agent Traumeel S in children with mucositis
undergoing stem cell transplantation (SCI).
The GI Company's lead Phase II clinical candidate, Intestinal Trefoil Factor (ITF), is an endogenous protein in Phase II development for the treatment oral mucositis
, a common, debilitating complication resulting from high-dose chemotherapy and / or radiotherapy.
Purpose: Oral mucositis
is a common and severe complication of head and neck radiation therapy.
SAN ANTONIO -- Saforis has been shown to reduce the incidence and severity of oral mucositis
in patients undergoing chemotherapy, Douglas E.
Thousand Oaks, CA, announced the US Food and Drug Administration (FDA) has approved Kepivance (palifermin), the first and only therapy to decrease the incidence and duration of severe oral mucositis
(mouth sores) in patients with hematologic cancers undergoing high-dose chemotherapy, with or without radiation, followed by a bone marrow transplant.